A global, proof-of-concept phase II trial of HMPL-523 in lupus-erythematosus

Next Previous
Trial Profile

A global, proof-of-concept phase II trial of HMPL-523 in lupus-erythematosus

Planning
Phase of Trial: Phase II

Latest Information Update: 10 Jan 2017

At a glance

  • Drugs HMPL 523 (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Proof of concept; Therapeutic Use

    • Most Recent Events

    • 10 Jan 2017 According to a Chi-Med media release, company expects to initiate this study in 2017.
    • 05 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top